一项评估 Frexalimab、SAR442970 或 Rilzabrutinib 对 16 至 75 岁原发性局灶节段性肾小球硬化症或微小病变病参与者的疗效和安全性的研究 (RESULT)
一项平行组治疗、2a 期、多中心、随机、双盲、安慰剂对照伞式研究,旨在评估 Frexalimab、SAR442970 和 Rilzabrutinib 在 16 至 75 岁原发性局灶节段性肾小球硬化症 (FSGS) 参与者中的疗效和安全性或微小病变病 (MCD)
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).
The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, brivekimig or rilzabrutinib compared with placebo in participants with primary FSGS or MCD aged 16 to 75 years.
Study details for each participant include:
The study duration will be up to 52 weeks. The treatment duration will be 24 weeks. There will be up to 16 visits.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Trial Transparency email recommended (Toll free for US & Canada)
- 电话号码:option 6 800-633-1610
- 邮箱:contact-us@sanofi.com
学习地点
-
-
-
Beijing、中国、100034
- 招聘中
- Investigational Site Number : 1560001
-
Chengdu、中国、610072
- 招聘中
- Investigational Site Number : 1560003
-
Shanghai、中国、200080
- 完全的
- Investigational Site Number : 1560004
-
-
-
-
Ontario
-
London、Ontario、加拿大、N6A 5A5
- 招聘中
- Investigational Site Number : 1240002
-
Toronto、Ontario、加拿大、M5G 1X8
- 招聘中
- Investigational Site Number : 1240004
-
-
Quebec
-
Montreal、Quebec、加拿大、H1T 2M4
- 招聘中
- Investigational Site Number : 1240001
-
Montreal、Quebec、加拿大、H3T 1C5
- 招聘中
- Investigational Site Number : 1240005
-
Québec、Quebec、加拿大、G1R 2J6
- 招聘中
- Investigational Site Number : 1240006
-
-
-
-
-
Budapest、匈牙利、1085
- 招聘中
- Investigational Site Number : 3480001
-
Pécs、匈牙利、7624
- 招聘中
- Investigational Site Number : 3480005
-
Szeged、匈牙利、6725
- 招聘中
- Investigational Site Number : 3480006
-
-
-
-
-
Taichung、台湾、404
- 招聘中
- Investigational Site Number : 1580001
-
Taipei、台湾、100
- 招聘中
- Investigational Site Number : 1580002
-
-
-
-
-
Kayseri、土耳其(türkiye)、38039
- 招聘中
- Investigational Site Number : 7920002
-
İzmit、土耳其(türkiye)、41001
- 招聘中
- Investigational Site Number : 7920001
-
-
-
-
Mexico City
-
Mexico City、Mexico City、墨西哥、14080
- 招聘中
- Investigational Site Number : 4840001
-
Mexico City、Mexico City、墨西哥、06720
- 招聘中
- Investigational Site Number : 4840005
-
-
Nuevo León
-
Monterrey、Nuevo León、墨西哥、64460
- 招聘中
- Investigational Site Number : 4840003
-
-
-
-
-
São Paulo、巴西、05403-000
- 招聘中
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760001
-
São Paulo、巴西、04038-002
- 招聘中
- Hospital do Rim e Hipertensão- Site Number : 0760002
-
-
São Paulo
-
Botucatu、São Paulo、巴西、18618-970
- 招聘中
- Universidade Estadual Paulista - Faculdade de Medicina de Botucatu- Site Number : 0760004
-
São Paulo、São Paulo、巴西、01139-000
- 招聘中
- Synvia Clinical- Site Number : 0760005
-
-
-
-
-
Athens、希腊、115 27
- 招聘中
- Investigational Site Number : 3000002
-
Heraklion、希腊、711 10
- 招聘中
- Investigational Site Number : 3000001
-
Ioannina、希腊、455 00
- 招聘中
- Investigational Site Number : 3000003
-
-
-
-
-
Berlin、德国、10117
- 招聘中
- Investigational Site Number : 2760002
-
Dresden、德国、01307
- 招聘中
- Investigational Site Number : 2760006
-
Hanover、德国、30625
- 招聘中
- Investigational Site Number : 2760003
-
-
-
-
-
Brescia、意大利、25123
- 招聘中
- Investigational Site Number : 3800001
-
-
Firenze
-
Florence、Firenze、意大利、50134
- 招聘中
- Investigational Site Number : 3800002
-
-
Milano
-
Monza、Milano、意大利、20900
- 招聘中
- Investigational Site Number : 3800004
-
-
Napoli
-
Naples、Napoli、意大利、80131
- 招聘中
- Investigational Site Number : 3800003
-
-
-
-
-
Olomouc、捷克语、779 00
- 招聘中
- Investigational Site Number : 2030002
-
Prague、捷克语、128 08
- 招聘中
- Investigational Site Number : 2030001
-
-
-
-
-
Banská Bystrica、斯洛伐克、975 17
- 招聘中
- Investigational Site Number : 7030003
-
Bratislava - Kramare、斯洛伐克、831 01
- 招聘中
- Investigational Site Number : 7030004
-
Martin、斯洛伐克、036 01
- 招聘中
- Investigational Site Number : 7030001
-
-
-
-
La Araucanía
-
Temuco、La Araucanía、智利、4781151
- 招聘中
- Investigational Site Number : 1520003
-
-
Reg Metropolitana de Santiago
-
Santiago、Reg Metropolitana de Santiago、智利、8330034
- 招聘中
- Investigational Site Number : 1520002
-
-
-
-
-
Créteil、法国、94010
- 招聘中
- Investigational Site Number : 2500002
-
Paris、法国、75015
- 招聘中
- Investigational Site Number : 2500001
-
-
-
-
Greater Poland Voivodeship
-
Poznan、Greater Poland Voivodeship、波兰、60-780
- 招聘中
- Investigational Site Number : 6160004
-
-
Lódzkie
-
Lodz、Lódzkie、波兰、02-213
- 招聘中
- Investigational Site Number : 6160001
-
-
Opole Voivodeship
-
Opole、Opole Voivodeship、波兰、45-418
- 招聘中
- Investigational Site Number : 6160002
-
-
-
-
Australian Capital Territory
-
Garran、Australian Capital Territory、澳大利亚、2605
- 招聘中
- Investigational Site Number : 0360003
-
-
Victoria
-
Parkville、Victoria、澳大利亚、3050
- 招聘中
- Investigational Site Number : 0360001
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- 招聘中
- University of Alabama -The Kirklin Clinic- Site Number : 8400007
-
-
California
-
Orange、California、美国、92868
- 招聘中
- University of California Irvine Medical Center- Site Number : 8400015
-
San Francisco、California、美国、94143
- 招聘中
- University of California San Francisco - Parnassus Heights- Site Number : 8400012
-
-
Florida
-
Tampa、Florida、美国、33612
- 招聘中
- University Of South Florida - Parent- Site Number : 8400025
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 招聘中
- Emory Children's Center- Site Number : 8400020
-
-
Illinois
-
Chicago、Illinois、美国、60611
- 招聘中
- Northwestern Memorial Hospital- Site Number : 8400014
-
Hinsdale、Illinois、美国、60521
- 招聘中
- Nephrology Associates of Northern Illinois and Indiana (NANI) - Hinsdale- Site Number : 8400017
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- University of Michigan Health System - Ann Arbor- Site Number : 8400010
-
-
Minnesota
-
Edina、Minnesota、美国、55435
- 招聘中
- InterMed Consultants - Edina Clinic- Site Number : 8400019
-
-
Nevada
-
Las Vegas、Nevada、美国、89107
- 主动,不招人
- DaVita Clinical Research - Las Vegas - North Rainbow Boulevard- Site Number : 8400018
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87109
- 招聘中
- Renal Medicine Associates- Site Number : 8400028
-
-
New York
-
New York、New York、美国、10032
- 招聘中
- Columbia University Irving Medical Center- Site Number : 8400001
-
The Bronx、New York、美国、10467
- 招聘中
- The Children's Hospital at Montefiore- Site Number : 8400027
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27599
- 招聘中
- UNC Kidney Center- Site Number : 8400021
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 招聘中
- Cleveland Clinic - Cleveland- Site Number : 8400029
-
-
Texas
-
Dallas、Texas、美国、75204
- 招聘中
- Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400024
-
El Paso、Texas、美国、79902
- 招聘中
- El Paso Kidney Specialists- Site Number : 8400005
-
Houston、Texas、美国、77054
- 招聘中
- Prolato Clinical Research Center- Site Number : 8400016
-
-
-
-
Leicestershire
-
Leicester、Leicestershire、英国、LE5 4PW
- 招聘中
- Investigational Site Number : 8260001
-
-
Manchester
-
Salford、Manchester、英国、M6 8HD
- 招聘中
- Investigational Site Number : 8260004
-
-
Oxfordshire
-
Oxford、Oxfordshire、英国、OX3 7LE
- 招聘中
- Investigational Site Number : 8260005
-
-
-
-
-
Amsterdam、荷兰、1105 AZ
- 招聘中
- Investigational Site Number : 5280001
-
-
-
-
-
Carnaxide、葡萄牙、2790-134
- 招聘中
- Investigational Site Number : 6200004
-
Lisbon、葡萄牙、1050-099
- 招聘中
- Investigational Site Number : 6200003
-
Matosinhos Municipality、葡萄牙、4464-513
- 完全的
- Investigational Site Number : 6200001
-
Porto、葡萄牙、4434-502
- 招聘中
- Investigational Site Number : 6200002
-
-
-
-
-
Córdoba、西班牙、14004
- 招聘中
- Investigational Site Number : 7240002
-
Madrid、西班牙、28007
- 招聘中
- Investigational Site Number : 7240008
-
Madrid、西班牙、28040
- 招聘中
- Investigational Site Number : 7240007
-
Valencia、西班牙、46026
- 完全的
- Investigational Site Number : 7240003
-
-
Andalusia
-
Seville、Andalusia、西班牙、41013
- 招聘中
- Investigational Site Number : 7240005
-
-
Catalunya [Cataluña]
-
Barcelona、Catalunya [Cataluña]、西班牙、08035
- 招聘中
- Investigational Site Number : 7240001
-
Barcelona、Catalunya [Cataluña]、西班牙、08025
- 完全的
- Investigational Site Number : 7240004
-
-
Navarre
-
Pamplona、Navarre、西班牙、31008
- 招聘中
- Investigational Site Number : 7240009
-
-
-
-
-
Buenos Aires、阿根廷、1431
- 招聘中
- Investigational Site Number : 0320001
-
Córdoba、阿根廷、5016
- 招聘中
- Investigational Site Number : 0320002
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Biopsy report indicative of primary FSGS or MCD, with supportive clinical presentation per Investigator's judgement.
- UPCR ≥3 g/g at screening, or ≥ 1.5 g/g in those with eGFR ≥ 60 mL/min/1.73 m2.
- eGFR ≥45 mL/min/1.73 m^2 at screening.
- Documented history of UPCR or UACR (or 24-hour urine protein or 24-hour urine albumin) reduction by >40% in response to corticosteroid or other immunosuppressive therapy when pre-treatment UPCR was ≥3.5 g/g or equivalent for UACR (or pre-treatment 24-hr urine protein was ≥3.5 g/day if 24-hour urine protein is used or equivalent for 24-hr urine albumin if 24-hour urine albumin is used).
- ≤10 mg/day prednisone or equivalent and stable starting at least 1 week prior to randomization.
- For those on a RAAS inhibitor prior to screening, the dose must be stable ≥4 weeks prior to screening; starting RAAS inhibitors or changing the dose will not be allowed during the double-blind or OLE treatment period.
- For those on an SGLT2 inhibitor prior to screening, the dose must be stable ≥4 weeks prior to screening; starting SGLT2 inhibitor treatment or changing the dose will not be allowed during the double-blind or OLE treatment periods.
- Body weight within 45 to 120 kg (inclusive) at screening.
Exclusion Criteria:
- Genetic or secondary FSGS or MCD. Those with APOL1 risk alleles are eligible.
- Collapsing variant of FSGS.
- ESKD requiring dialysis or transplantation.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Placebo
Matching placebo |
placebo treatment |
|
实验性的:Frexalimab
Frexalimab active dose |
frexalimab treatment |
|
实验性的:Brivekimig
Brivekimig active dose |
brivekimig treatment |
|
实验性的:Rilzabrutinib
Rilzabrutinib active dose |
rilzabrutinib treatment |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
尿蛋白与肌酐比值 (UPCR) 降低百分比
大体时间:从基线到第 12 周
|
从基线到第 12 周
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Frexalimab 和 rilzabrutinib 的血浆浓度以及 SAR442970 的血清浓度
大体时间:直至第 48 周
|
直至第 48 周
|
|
|
针对 frexalimab 和 SAR442970 的抗药物抗体 (ADA) 的出现
大体时间:直至第 48 周
|
直至第 48 周
|
|
|
Percentage of participants achieving FSGS partial remission endpoint
大体时间:At Week 12
|
Defined as UPCR ≤1.5 g/g and >40 % reduction of UPCR from baseline |
At Week 12
|
|
Percentage of participants achieving CR
大体时间:At Week 12
|
Defined as UPCR ≤0.3 g/g |
At Week 12
|
|
Incidence of treatment-emergent adverse events, treatment-emergent serious adverse events (SAEs), treatment-emergent adverse events of special interest (AESIs) and IMP discontinuation due to TEAEs during the study
大体时间:Treatment emergent period, up to Week 48
|
TEAEs, including clinically significant changes in vital signs, electrocardiogram [ECG], and laboratory evaluation |
Treatment emergent period, up to Week 48
|
合作者和调查者
赞助
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- ACT18064
- 2024-511775-15 (注册表标识符:CTIS)
- U1111-1301-2676 (注册表标识符:WHO)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.